Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0562 + Durvalumab/Tremelimumab in Advanced Solid Tumors
NCT02705482Phase 1Completed
- Sponsor
- MedImmune
- Start
- Mar 2016
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of tavolimab in solid tumor (advanced stage) (2 arms), sponsored by MedImmune. Primary endpoint: Safety (AEs, SAEs, DLTs) at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
tavolimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02705482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705482.